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Abstract
For the treatment of chronic ocular diseases such as glaucoma, continuous instillations of eye drops are needed. However,
frequent administrations of hypotensive topical formulations can produce adverse ocular surface effects due to the active
substance or other components of the formulation, such as preservatives or other excipients. Thus the development of
unpreserved formulations that are well tolerated after frequent instillations is an important challenge to improve
ophthalmic chronic topical therapies. Furthermore, several components can improve the properties of the formulation in
terms of efficacy. In order to achieve the mentioned objectives, we have developed formulations of liposomes (150–
200 nm) containing components similar to those in the tear film and loaded with the hypotensive melatonin analog 5-
methoxycarbonylamino-N-acetyltryptamine (5-MCA-NAT, 100 mM). These formulations were combined with mucoadhesive
(sodium hyaluronate or carboxymethylcellulose) or amphiphilic block thermosensitive (poloxamer) polymers to prolong the
hypotensive efficacy of the drug. In rabbit eyes, the decrease of intraocular pressure with 5-MCA-NAT-loaded liposomes that
were dispersed with 0.2% sodium hyaluronate, 39.162.2%, was remarkably higher compared to other liposomes formulated
without or with other bioadhesive polymers, and the effect lasted more than 8 hours. According to the results obtained in
the present work, these technological strategies could provide an improved modality for delivering therapeutic agents in
patients with glaucoma.
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Introduction
Ophthalmic drug delivery is one of the most interesting and
challenging endeavors facing the pharmaceutical sciences. The
anatomy, physiology and biochemistry of the eye render this organ
exquisitely impervious to foreign substances [1]. So to get the
desired therapeutic effect, repeated and frequent applications of
topical ophthalmic formulations are usually required.
Glaucoma is a multifactorial, progressive and neurodegenera-
tive disease characterized by atrophy of the optic nerve and loss of
retinal ganglion cells that can eventually lead to loss of visual
acuity and visual field [2,3]. High intraocular pressure (IOP) is
considered the greatest risk factor for the development of
glaucoma, so most treatments consist of the chronic application
of eye drops containing hypotensive agents. Despite the usefulness
of topical administration, glaucoma treatments are usually
associated with adverse reactions generated by the frequent
exposure to drugs and excipients undergone by the eye. Among
the excipients, preservatives can induce ocular surface alterations
[4,5,6,7] that contribute to the development of secondary
ophthalmic diseases such as the dry eye syndrome [8,9]. This in
turn can compromise patient compliance. However, the elimina-
tion of preservatives from ophthalmic formulations is not always
enough to avoid side effects on the ocular surface. For that reason,
the incorporation of new components in formulations with
beneficial properties for the eye and able, at the same time, to
increase the bioavailability of the drug, results of great interest in
this field.
Melatonin receptors have been identified in the cornea, ciliary
body, lens, choroid, and sclera and play a role in aqueous humor
dynamics [10,11]. In recent years, the role of melatonin and its
analogues in the control of IOP has been investigated. The
melatonin analogue 5-methoxycarbonylamino-N-acetyltryptamine
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(5-MCA-NAT) induces an IOP reduction after topical adminis-
tration in normotensive rabbits [12,13] and glaucomatous
monkeys [14]. In a previous work, the hypotensive effect of 5-
MCA-NAT was enhanced up to 30% (maximum IOP reduction)
with the use of mucoadhesive polymers, although the effect could
not be prolonged longer than 6 hours [15].
Ophthalmic formulations of liposomes have been proposed to
increase the efficacy of topical ophthalmic formulations and,
depending on composition, to resemble the tear film lipid layer.
Liposomes are spherical vesicles composed of an aqueous core
enclosed by concentric phospholipids bilayers [16]. On the ocular
surface, these vesicles establish a very tight contact with tissues,
thus increasing the residence time of the formulation and,
subsequently, the corneal penetration of the drug [17]. When
active substances are included in these systems they are protected
from the medium and the half-life is usually increased.
Our research group recently developed a novel artificial tear
based on liposomes that improve the quality and stability of an
unstable tear film [18]. In this formulation, liposomes were
dispersed in aqueous solutions of polymers with mucoadhesive
properties. The addition of these polymers had positive effects
attributed to their rheological and biophysical properties, which
are similar to those of mucins involved in the maintenance of the
tear film on the ocular surface. Bioadhesive polymers also provide
long-lasting hydration and lubrication of the ocular surface while
minimizing the loss of formulation through the nasolacrimal
drainage pathway [19].
Other materials, such as thermosensitive amphiphilic block
copolymers, namely poly (ethylene oxide)–poly (propylene oxide)–
poly (ethylene oxide) (PEO–PPO–PEO, poloxamers), have been
recently investigated in the design of novel drug delivery systems.
When poloxamers are in solution, they form micelles and,
depending on the concentration and temperature, are able to
self-organize and transform into a viscous gel, allowing a
controlled release of the drug [20].
In the present study we have used hybrid combinations of
liposomes, mucoadhesive or thermosensitive polymers, and the
intraocular hypotensive agent 5-MCA-NAT. These pharmaceuti-
cal formulations were characterized in terms of physicochemical
properties, in vitro release of 5-MCA-NAT, in vivo tolerance and
in vivo intraocular pressure reduction, after topical ophthalmic
application in nonsedated normotensive rabbits.
Materials and Methods
Materials
The melatonin agonist 5-MCA-NAT was purchased from
Tocris Bioscience (Bristol, UK) and 1.2-propylene glycol (PG)
from Guinama (Valencia, Spain). Sodium hyaluronate (SH, Mw
400,000–800,000 g/mol) and sodium carboxymethylcellulose
(CMC, 400–800 cps 2% solution at 20uC) were purchased from
Abarán Materias Primas S.L. (Madrid, Spain). Phospholipon 90G
purified from soy lecithin (.95% phosphatidylcholine, PC) was
purchased from Phospholipid GmbH (Cologne, Germany).
Cholesterol (Cht) and a-tocopherol (vitE) were acquired from
Sigma Chemical Co. (St. Louis, MO, USA). Isotonic NaCl
solution was prepared with ultrapure Milli-Q water (EMD
Milllipore, Darmstadt, Germany). Poloxamer 407 (PX407) and
Poloxamer 188 (PX188) were gifts from BASF S.A. (Buenos Aires,
Argentina).
Methods
1. Quantitation of 5-MCA-NAT by high pressure liquid
chromatography (HPLC). Quantitative analyses of 5-MCA-
NAT were performed with a HPLC instrument (Gilson, Mid-
dleton, WI, USA) composed of a solvent delivery pump (305
model), UV-visible detector (118 model), and controller software
(UniPoint, all by Gilson). The injector was equipped with a 20 ml
loop (7125 Rheodyne, Berkeley, CA, USA). The chromatographic
separation was achieved as described previously [12] by a reversed
phase protocol with a Mediterranea Sea18 column
(25 cm64 mm, 5 mm particle size; Teknokroma, Barcelona,
Spain). The mobile phase was a mixture of methanol (Panreac,
Barcelona, Spain) and ultrapure milliQ water (40:60 v/v). The
flow rate was set at 0.8 ml/min and the eluent was monitored at
244 nm.
2. Sample preparation. Five formulations (Table 1) con-
taining 100 mM 5-MCA-NAT were prepared: F1, aqueous
solution of 5-MCA-NAT; F2, 5-MCA-NAT-loaded liposomes;
F3, 5-MCA-NAT-loaded liposomes with 0.2% SH; F4, 5-MCA-
NAT-loaded liposomes with 0.5% CMC; and F5, 5-MCA-NAT-
loaded liposomes with PX (PX407 and PX188; 12/8, w/w).
Formulation F1, the aqueous non-liposomal solution of 5-MCA-
NAT, was prepared by dissolution of 5-MCA-NAT in PG (10 mg/
mL) and further dilution with an aqueous solution of NaCl. The
final formulation contained 100 mM 5-MCA-NAT, 0.275% PG,
and 0.788% NaCl. 5-MCA-NAT-loaded liposomes (F2, F3, F4,
and F5) were prepared following the procedure described by
Bangham [21] and modified by Vicario-de-la-Torre [22].
According to the procedure PC, Cht and vitE (8:1:0.08) were
dissolved in chloroform in a round-bottom flask. Then, the organic
solvent was slowly removed at 33uC with a rotator evaporator to
produce a thin film of dry lipids on the inner surface of the flask.
The dry film was then hydrated with an aqueous solution of
200 mM 5-MCA-NAT to produce the 5-MCA-NAT-loaded
liposomes. The liposomes were extruded ten times through
0.22 mm pore polycarbonate membranes (Nucleopore Lipex
Biomembrane, Vancouver, Canada). To ensure full lipid hydra-
tion, vesicles were allowed to mature overnight under refrigera-
tion. After that, stock formulations were diluted (1:2) with different
aqueous solutions to achieve the final liposomal formulations
(Table 1): F2, 0.788% NaCl and 0.275% PG; F3, 0.4% SH in
0.788% NaCl and 0.275% PG; F4, 1% CMC in 0.788% NaCl
and 0.275% PG); F5, PX407 and PX188 (24/16, w/w) in 0.17%
NaCl and 0.275% PG. The concentration of NaCl was adjusted to
attain osmolarity values in the final formulations within an
acceptable range for ophthalmic administration [23]. Due to the
high influence of PX in the osmolarity of the formulations [24], a
lower concentration of NaCl was used to adjust F4. Final
liposomal formulations were sterilized by filtration through
0.22 mm pore membranes.
3. Determination of the encapsulation efficiency of
liposomes. The encapsulation efficiency of 5-MCA-NAT in
the liposomes was determined upon separation by centrifugation
(18,000 rpm, 4uC, 20 min) from the dispersing medium contain-
ing non-encapsulated 5-MCA-NAT. The amount of free 5-MCA-
NAT in the supernatant was determined in triplicate by HPLC.
The determination of the percentage of drug loading (PDL) in
liposomes, expressed as mean 6 standard deviation, was
calculated using the following equation [25]:
PDL~100 x total drug added mgð Þ{ free drug mgð Þ½ =
total drug added mgð Þ
The entire amount of 5-MCA-NAT in the liposomal formula-
tions was measured by dissolving liposomes with the appropriate
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amount of acetonitrile. Solutions were then centrifuged
(15,000 rpm, 4uC, 20 min) and the supernatant analyzed in
triplicate by HPLC.
4. Determination of pH, osmolarity, and viscosity. The
pH of the formulations was measured with a calibrated pH meter
(model 230; Mettler, Barcelona, Spain) equipped with an InLab
Microelectrode (Mettler). Measurements were performed in
triplicate at room temperature (25uC).
Osmolarity was analyzed by a vapor pressure osmometer
(model K-7000 Knauer, Berlin, Germany). Before performing the
analyses, the osmometer was calibrated with a solution of NaCl
(400 mOsm). The determinations were made in triplicate at 33uC
(ocular surface temperature) [26].
Viscosity of liposomal samples was assessed in triplicate at 33uC
with a thermostatically controlled rheometer (HaakeRheostress
R1, Düsseldorf, Germany) using a parallel plate geometry
(diameter 60 mm, gap 0.5 mm). The viscosity was calculated at
a shear rate of 100 s21, which was within the linear viscoelastic
range for all of the formulations.
5. Determination of particle size and zeta
potential. Measurements of liposome particle size and zeta
potential were carried out by photon correlation spectroscopy
(PCS, Zetatrac, Largo, FL, USA). For the analyses, formulations
were diluted 1/20 (v/v) in an aqueous medium. All determinations
were performed in triplicate at room temperature (25uC).
6. Hypotensive efficacy studies in vivo: IOP
determinations. In this work, experiments were performed in
both eyes of nonsedated normotensive male New Zealand white
rabbits (2–2.5 kg). Each formulation was evaluated in 10 animals
(n = 20 eyes) and each control in 5 (n = 10 eyes). In order to reduce
the number of rabbits, the same animals were used multiple times
as experimental and control. The animals were kept in individual
cages with free access to food and water and maintained in a
controlled 12/12 h light/dark cycle. All of the protocols herein
were approved by the Ethics Committee for Animal Research of
Complutense University of Madrid. Also, animal manipulations
followed institutional guidelines, European Union regulations for
the use of animals in research, and the ARVO (Association for
Research in Vision and Ophthalmology) statement for the use of
animals in ophthalmic and vision research.
IOP was measured with a Tonovet rebound tonometer (Tiolat,
Helsinki, Finland). With this technique IOP is assessed without the
need of topical anesthesia. For each eye, IOP was set at 100% with
two basal readings taken 30 min before and immediately before
the instillation. Then a single dose of the formulation (25 mL) was
applied to both eyes. IOP determinations were performed once
every hour over the next 8 hours. As a control, rabbits received
formulations without the hypotensive agent. The administration
protocol included a washout period of at least 48 hours between
experiments.
7. In vitro drug release. The release of 5-MCA-NAT from
the different formulations was studied using a dialysis method. To
do this, a dialisys membrane (Spectra/Por Float-A-Lyzer G2;
20,000 MW cut off; Iberlabo, Madrid, Spain) was employed
(0.8 mL of sample). Three membranes were prepared for each
formulation. A conventional solution of 100 mM 5-MCA-NAT
without liposomes was used as reference. Dialysis membranes were
placed inside a flask with 50 mL of a phosphate buffered solution
isotonized with NaCl (pH 7.4). The flask was kept on a magnetic
stirrer and stirring was maintained at 100 rpm at 33uC. 1 mL of
release sample was withdrawn at pre-set times (5 min, 15 min,
30 min, once every hour over a period of 8 and 24 hours). The
release of 5MCANAT was analyzed by HPLC following the above
mentioned method.
8. In vivo tear osmolarity measurements. This study was
restricted to formulations F3 (5-MCA-NAT-loaded liposomes
dispersed in 0.2% sodium hyaluronate) and F4 (5-MCA-NAT-
loaded liposomes dispersed in 0.5% carboxymethylcellulose), that
provided the highest in vivo hypotensive effect among all the
tested formulations. An isotonic saline solution was used as control.
Each formulation (control included) was tested in both eyes of
three nonsedated male New Zealand white rabbits (n = 6 eyes).
Tear osmolarity was measured with the TearLab Osmolarity
System (TearLab Corporation, San Diego, CA, USA). The device,
stored in a temperature and humidity controlled room, was re-
calibrated using electronic check cards at the beginning of each
test session following the manufacturer’s guidelines. Tear samples
of 50 nL were collected from the lower lateral meniscus of the
eyes. To avoid fluctuation of tear osmolarity, all the measurements
were made between 9 and 11 AM. Both eyes of rabbits were used
for the evaluations. Measurements were taken before the
administration of 25 mL of the formulation and 5, 15, 30 and
60 min after instillation.
9. In vivo short-term tolerance study. This study was
restricted to formulations F3 (5-MCA-NAT-loaded liposomes
dispersed in 0.2% sodium hyaluronate) and F4 (5-MCA-NAT-
loaded liposomes dispersed in 0.5% carboxymethylcellulose), that
provided the highest in vivo hypotensive effect among all the
tested formulations.
The experiment was carried out on both eyes of six male New
Zealand rabbits. A single administration of 25 mL of the
formulation were administered in the right eye of the animal.
Table 1. Nomenclature and composition of the 5-MCA-NAT formulations.
Formulation Composition Polymer
F1 100 mM 5-MCA-NAT, 0.275% PG and 0.788% NaCl -
F2 100 mM 5-MCA-NAT, 0.275% PG, 10 mg/mL PC, and
0.788% NaCl
-
F3 100 mM 5-MCA-NAT, 0.275% PG, 10 mg/mL PC, 0.2% SH and
0.788% NaCl
Sodium hyaluronate
F4 100 mM 5-MCA-NAT, 0.275% PG, 10 mg/mL PC, 0.5% CMC and
0.788% NaCl
Carboxymethylcellulose
F5 100 mM 5-MCA-NAT, 0.275% PG, 10 mg/mL PC, PX407 and
PX188 (12/8 w/w), and 0.479% NaCl
Poloxamer
5-MCA-NAT: 5-methoxycarbonylamino-N-acetyltryptamine, PG: propylene glycol, PC: phosphatidylcholine, SH: sodium hyaluronate, CMC: carboxymethylcellulose, PX:
poloxamer (PX407 and PX188 12/8 w/w).
doi:10.1371/journal.pone.0110344.t001
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The contralateral eye was used as control and being instilled with
the same volume of an isotonic solution of NaCl (pH 7.4).
Clinical symptoms and signs were evaluated in accordance with
a protocol described previously [27]. Ocular surface evaluation
was made before the instillation of the formulation or control, and
then 1, 8 and 24 h after their administration. The short-term
tolerance was evaluated by macroscopic examination of the eye
surface of the animal and graded from 0–2, indicating the absence
or presence of the following clinical signs: loss of corneal
transparency, conjunctival signs (hyperemia, edema), eyelid
swelling, and intense blinking (what would show a lack of
tolerance).
10. Statistical analysis. Intraocular hypotensive reduction
was expressed as means 6 standard error of the means (SEM).
Other parameters as means 6 standard deviation (SD) were also
evaluated. Statistical differences between two mean values were
evaluated by two-tailed Students t-test. If necessary, an analysis of
variance (ANOVA) was employed. Results were taken as
significantly different at p-values less than 0.05.
Results
1. 5-MCA-NAT dose determination
The HPLC method to quantify 5-MCA-NAT was validated
with respect to linearity, accuracy, and reliability in the range of
concentrations between 5 and 50 mg/mL. In all cases, the method
allowed sufficient separation of the drug from the vehicle. The
retention time of 5-MCA-NAT was 10.760.5 minutes. There
were non-significant differences (p = 0.57) between the theoretical
concentration of 5-MCA-NAT (100 mM, ,27.53 mg/mL) and the
experimental values obtained (28.561.07 mg/mL). The percent-
age of 5-MCA-NAT loaded in the liposomes was 7.963.5%,
relative to the entire amount of drug in the liposomal formulation.
Taking into consideration that the volume of the instilled
formulation in rabbit eyes was 25 mL, the dose of 5-MCA-NAT
administered was 0.7160.04 mg.
2. pH, osmolarity, and viscosity
The pH and osmolarity were measured for all formulations, and
the viscosity was measured for liposomal formulations F2–F5
(Table 2). Formulation F1, without liposomes, had an acidic pH of
5.6. The incorporation of lipid vesicles in formulation F2 produced
an increase of pH to 6.9, a nearly neutral value. The incorporation
of polymer in formulations F3, F4, and F5 produced a minor
decrease in pH, with values of 6.4, 6.5, and 6.5 respectively. The
osmolarity of formulations F1, F2, F3, and F4 were within the
range of isotonicity (Table 2). Formulation F5, with an osmolarity
value of 23763.1 mOsm, was hypotonic. The lowest viscosity,
1.2 mPa?s, was obtained in F2 (Table 2), the liposomal formula-
tion without polymers. The addition of sodium hyaluronate 0.2%
(F3) and carboxymethylcellulose 0.5% (F4) increased the viscosity
of the formulations to 2.0 mPa?s and 7.3 mPa?s, respectively. The
liposomal formulation with poloxamer (F5) had the highest
viscosity, 28.3 mPa?s.
3. Mean particle size and zeta potential of liposomal
formulations
All of the liposomal formulations showed unimodal size
distributions (Figure 1), and the average particle sizes were less
than 200 nm in all cases (Table 3). The average zeta potential was
neutral (range between 210 to 10 mV) in all cases (Table 3).
4. Effect of 5-MCA-NAT formulations on IOP in rabbits
All formulations reduced IOP in normotensive rabbits though
the maximal effects were different for each formulation (Figure 2).
The maximum percentage of IOP reduction, the area under the
DIOP (%) time curve from 0 to 8 hours (estimated by the
trapezoidal rule) and the duration of the hypotensive effect (h),
were calculated for all the formulations (Table 4). In addition,
several other IOP parameters were considered: mean of the
minimum and maximum IOP, and mean difference between
maximum and minimum IOP (Table 5). The IOP values
measured were within the range of 8 to 16 mm Hg (Table 5).
Formulation F3, composed of 5-MCA-NAT-loaded liposomes
with 0.2% SH, produced the maximum hypotensive effect
(Figure 2, Tables 4 and 5). This formulation provided an IOP
reduction of 39.1362.21%. The second highest value,
36.7262.77%, was achieved by F4, composed of 5-MCA-NAT-
loaded liposomes with 0.5% CMC. There were no significant
differences between F3 and F4 with regard to the lowering of IOP
(p = 0.55). The rest of the formulations provided significantly lower
values (p,0.01 in all cases). For formulations F2, F3 and F4, the
hypotensive effect was maintained for longer than 8 hours (p,0.05
for each formulation compared with the corresponding vehicle)
(Figure 2 and Table 4). For F5, composed of 5-MCA-NAT-loaded
liposomes dispersed in PX, the hypotensive effect lasted only 5
hours. Differences in the IOP can be observed among the
formulations at 4 time points: 3, 6, 7 and 8 hours (p,0.05)
although these differences are not systematically generated by the
same formulation. Regarding the area under the DIOP (%) time
curve from 0 to 8 hours, AUC0
8 h, the highest value was shown
with F3 (156.15614.71), while the lowest with F5 (85.20616.83).
5. In vitro release studies
The in vitro release behavior of the solution of 5-MCA-NAT
(F1), 5-MCA-NAT-loaded liposomes dispersed in NaCl (F2), 5-
MCA-NAT-loaded liposomes dispersed in 0.2% SH (F3) and 5-
MCA-NAT-loaded liposomes dispersed in 0.5% CMC (F4), is
summarized in the cumulative percentage release shown in
figure 3.
The release rate of the drug was higher for the solution of 5-
MCA-NAT (F1), while the rate of release from 5-MCA-NAT-
loaded liposomes dispersed in SH (F3) or CMC (F4) was lower
than that of conventional liposomes (F2). Statistically significant
differences between the solution of 5-MCA-NAT (F1) and
liposomal formulations (F2–F4) were found after 1 hour of the
beginning of the study (p,0.05 at all the time points studied).
Comparing liposomal formulations, non-significant differences
were found between conventional liposomes (F2) and liposomes
dispersed in SH (p.0.25 in all cases). In the case of F4, 5-MCA-
NAT released from liposomes resulted significantly lower to the
ones that were found for the solution of 5-MCA-NAT (F1) or for
conventional liposomes (F2) after 1 hour of the beginning of the
study and up to 8 hours (p,0.003 in all cases). From 6 to 8 hours,
a significant different release rate can be observed between F3 and
F4, being F4 (5-MCA-NAT-liposomes dispersed with CMC) the
formulation that showed a slower release profile (p,0.05).
6. In vivo tear osmolarity
Following the guidelines for the use of experimental animals, the
number of rabbits was diminished by selecting the formulations
that showed the best in vivo hypotensive effect: 5-MCA-NAT-
loaded liposomes dispersed in 0.2% SH (F3) and 5-MCA-NAT-
loaded liposomes dispersed in 0.5% CMC (F4). Results are
collected in table 6.
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Instillation of a single drop of saline solution (Control Group)
decreased the tear osmolarity for 5 min. However, 30 and 60 min
later, osmolarity values were not significantly different to basal
(p = 0.12). When animals were treated with liposomes combined
with bioadhesive polymers (F3 and F4) the tear osmolarity
diminished significantly at any time in comparison to basal
(p = 0.04 and p = 0.0026, respectively).
7. In vivo tolerance study
Before testing, all animals had a normal ocular surface and
corneal transparency. None had any conjunctival disorders
including hyperemia or edema, eyelid swelling, or intense blinking
(grade 0). Animals showed no discomfort or irritation during the
test or within 24 h after the administration of formulations F3 and
F4, which contained 5-MCA-NAT-loaded liposomes dispersed in
0.2% SH and 0.5% CMC, respectively. The cornea remained
transparent (no vessels) throughout the assay (grade 0) and the
coloration of the conjunctiva remained normal (grade 0). No
animal presented signs of mucus secretion.
Discussion
In general, topical ophthalmic anti-glaucoma therapies combine
the use of one or more hypotensive drugs with several instillations
per day in chronic treatments. In these patients, the eye surface is
continuously exposed to drugs and preservatives that produce, in
most cases, ocular surface alterations and generally lead to a
therapeutic failure [28]. Eye drops for chronic treatments should
include components that are well tolerated for the ocular surface
and, at the same time, enable enhanced drug bioavailability
Table 2. pH, osmolarity, and viscosity data of the 5-MCA-NAT formulations.
Formulation Polymer pH Osmolarity (mOsm) Viscosity (mPa?s)
F1 - 5.660.02 295.860.5 -
F2 - 6.960.03 303.860.2 1.260.1
F3 Sodium hyaluronate 6.460.02 307.160.3 2.060.04*
F4 Carboxymethylcellulose 6.560.01 294.260.5 7.360.1*
F5 Poloxamer 6.560.01 237.263.1* 28.361.4*
Data are expressed as means 6 SD (n = 3).
*Significant differences with formulation F2 (p-value,0.05).
doi:10.1371/journal.pone.0110344.t002
Figure 1. Size distribution of 5-MCA-NAT-loaded liposomes dispersed in NaCl (F2), 0.2% sodium hyaluronate (F3), 0.5%
carboxymethylcellulose (F4) and 12/8 w/w poloxamer (F5).
doi:10.1371/journal.pone.0110344.g001
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Table 3. Mean diameter and zeta potential of the 5-MCA-NAT liposomal formulations.
Formulation Polymer Size (nm) Zeta potential (mV)
F1 - - -
F2 - 155.164.0 10.262.7
F3 Sodium hyaluronate 162.867.7 8.762.7
F4 Carboxymethylcellulose 188.5616.9* 7.264.5
F5 Poloxamer 181.8612.8* 6.460.9
Data are expressed as means 6 SD (n = 3).
*Significant differences with formulation F2 (p-value,0.05).
doi:10.1371/journal.pone.0110344.t003
Figure 2. Ocular hypotensive effect of 5-MCA-NAT formulations. F1, solution of 5-MCA-NAT. F2, 5-MCA-NAT-loaded liposomes dispersed in
NaCl; F3, 5-MCA-NAT-loaded liposomes dispersed in 0.2% sodium hyaluronate; F4, 5-MCA-NAT-loaded liposomes dispersed in 0.5%
carboxymethylcellulose; F5, 5-MCA-NAT-loaded liposomes dispersed in 12/8 w/w poloxamer. Vehicles without 5-MCA-NAT were used as control
in each case. Data are expressed as the mean 6 SEM (n = 20).
doi:10.1371/journal.pone.0110344.g002
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[29,30]. In general, toxicity of formulations can be reduced by
removing preservatives from the composition. However, in some
cases the toxic effect of the drug still remains [31,32,33]. The
inclusion of bioadhesive polymers have demonstrated to increase
the tolerance of formulations while extending the effect of
hypotensive drugs such as timolol maleate [34]. Nevertheless,
the benefits produced by these polymers in terms of efficacy are
limited, so it becomes necessary to use other technological
approaches, such as combination of the drugs with other colloidal
systems. Liposomes have gained considerable attention for ocular
drug delivery. They have been primarily investigated as a modality
to enhance corneal drug absorption through the ability to come
into intimate contact with the corneal and conjunctival surfaces,
thereby increasing the ocular drug penetration [17].
In this study, we designed novel liposomal formulations loaded
with 5-MCA-NAT, a melatonin derivative that reduces IOP
[12,15]. The liposomes that we employed (150–200 nm, 6–10 mV
zeta potential) simulate the lipid composition of the pre-ocular tear
film and have demonstrated to be effective in the treatment of the
dry eye syndrome [18]. The anti-glaucoma formulations of the
current study were designed to (a) control the delivery of 5-MCA-
NAT, thus prolonging the hypotensive effect, and (b) replenish the
tear film, which may improve an ocular surface damaged by
chronic exposure to topical treatments. To achieve the objectives,
we prepared liposomes with the biocompatible components PC,
Cht, and vitE – all of which are present in the natural tear film –
that were loaded with 100 mM 5-MCA-NAT. Once prepared, the
liposomes were dispersed in an isotonic aqueous solution alone or
with the bioadhesive biopolymers SH or CMC, or a thermo-
sensitive polymer, PX, to determine whether or not the use of
these combinations would enhance the hypotensive effect of 5-
MCA-NAT. The bioadhesive polymers and concentrations were
selected among the available existing commercial artificial tear
products [35]. A conventional solution of 100 mM 5-MCA-NAT
without liposomes was used as the reference.
All the formulations developed satisfied the given requirements
of pH and osmolarity for ophthalmic solutions [36]. Regarding pH
values, the presence of lipid vesicles in formulation F2 produced a
slight increase of pH to a nearly neutral value, probably due to the
presence of PC in the formulation. The incorporation of polymers
in formulations F3, F4, and F5 produced minor decreases in pH,
presumably due to the acidic nature of SH, CMC and PX. For the
formulations F2–F5, the pH values were nearly neutral, thus
helping to maintain the optical properties of the eye surface,
epithelial cell functions, and cellular homeostasis. With respect to
the osmolarity, all of the formulations were within an acceptable
range for ophthalmic administration [23].
To obtain a homogeneous film after instillation, the viscosity of
a formulation should be similar to that of natural tears, 1–9 mPa?s
[37,38]. Previous studies showed that the most significant relative
improvement in ocular bioavailability occurred for vehicles in the
viscosity range from 1 to 15 mPa?s [39,40]. In our study, the
viscosities of formulations with bioadhesive polymers were within
this range, and the most effective formulations for reducing IOP,
F3 and F4, had viscosity values of 2.0 mPa?s and 7.3 mPa?s,
respectively. The formulation F5 had the highest viscosity,
28.3 mPa?s, but it was no more effective in reducing IOP than
were the non-liposomal F1 or the liposomal F2 without a
bioadhesive polymer. This anomalous behavior of F5 (liposomes
dispersed with Poloxamer) could be associated with its high
viscosity and sol–gel phase transition phenomena [41].
The bioadhesive properties and rheological behavior of SH and
CMC are widely described [42,43]. Mucins present in the pre-
ocular tear film can interact with the bioadhesive polymers and




8 h (%?h) Duration (h)
F1 - 29.2762.42 118.02614.62 7
F2 - 29.4462.40 112.07615.93 +8
F3 Sodium hyaluronate 39.1362.21* 156.15614.71* +8
F4 Carboxymethylcellulose 36.7262.77* 131.84616.81* +8
F5 Poloxamer 29.1262.11 85.20616.83 5
IOP, intraocular pressure; Maximum IOP reduction (%), percentage of reduction 6 SEM; AUC0
8 h, DIOP (%) versus time (h) from 0 to 8 hours. Data are expressed as
means 6 SEM (n = 20 eyes).
*Significant differences with formulation F2 (p-value,0.05).
doi:10.1371/journal.pone.0110344.t004
Table 5. IOP parameters over 8 hours.
Formulation IOPmax IOPmin DIOP
F1 15.561.8 10.161.8 5.461.7
F2 14.761.8 9.761.4 5.061.6
F3 16.261.9 9.361.5 6.961.8
F4 14.763.0 8.661.5 6.162.5
F5 13.260.5 8.961.1 4.361.3
IOP, intraocular pressure in mmHg, IOPmax, mean maximum IOP; IOPmin, mean minimum IOP; DIOP, mean difference between IOPmax and IOPmin. Data are expressed as
means 6 SEM (n = 20 eyes).
doi:10.1371/journal.pone.0110344.t005
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increase the residence time of the formulation on the eye surface
and improve drug bioavailability. Formulations F2 (5-MCA-NAT-
liposomes), F3 (5-MCA-NAT-liposomes dispersed with SH) and
F4 (5-MCA-NAT-liposomes dispersed with CMC) present hypo-
tensive effect up to 8 hours after a single administration unlike
formulation F1 (5-MCA-NAT dissolved in 0.788% NaCl and
0.275% PG). This effect can be attributed to possible interactions
between components of the formulations (liposomes and bioadhe-
sive polymers) with the ocular surface (mucins and/or tear film).
In vitro release studies also corroborate these results. Formulation
F4 (5-MCA-NAT-liposomes dispersed with CMC) shows signifi-
cant differences in the release rate from 6 h to 8 h with the rest of
formulations and a tendency to extend the hypotensive effect in
animals. Taking into account that hypertensive animals show
higher IOP decrease after the use of hypertensive drugs (in
comparison to normotensive animals), an induced hypertensive
Figure 3. In vitro release curve of 5-MCA-NAT formulations in phosphate buffered solution at 336C. F1: solution of 5-MCA-NAT; F2: 5-
MCA-NAT-loaded liposomes dispersed in NaCl; F3: 5-MCA-NAT-loaded liposomes dispersed in 0.2% sodium hyaluronate; F4: 5-MCA-NAT-loaded
liposomes dispersed in 0.5% carboxymethylcellulose. * Significant differences between formulations F2–F4 and formulation F1 (reference, p-value,
0.05).
doi:10.1371/journal.pone.0110344.g003
Table 6. Tear osmolarity in the 3 Study Groups.
t (min) Control Group F3 Group F4 Group
0 325.263.8 324.362.8 323.761.7
5 311.363.0 314.963.3* 316.761.0**
30 326.763.6 314.062.9* 313.263.4*
60 324.664.1 315.463.6* 311.861.9**
Control Group: animals were administered 25 mL of saline solution in both eyes; F3 Group animals were instilled 25 mL of 5-MCA-NAT-loaded liposomes dispersed in
0.2% SH (F3) in both eyes; F4 Group: animals received 25 mL of 5-MCA-NAT-loaded liposomes dispersed in 0.5% CMC (F4). Data are expressed as means 6 SD (n = 6).
*Significant differences with Control Group (p-value,0.05).
**Significant differences with Control Group (p-value,0.01).
doi:10.1371/journal.pone.0110344.t006
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animal models might be useful to appreciate differences in the
extension of the hypotensive effect [44,45].
In addition, these polymers hydrate and protect the ocular
surface by forming a film that covers the eye. So, the liposomes
dispersed with bioadhesive polymers contribute to the modulation
of drug delivery by adequately mixing with the natural tears that
cover the ocular surface. The liposomes also reduce water
evaporation from tears and help improve symptoms such as
dryness, redness, and visual impairment associated with dry eyes.
The mucoadhesive behavior of these hybrid formulations was
exhibited when rabbit eyes’ tear osmolarity decreased to reach
osmolarity values similar to the formulations F3 and F4 that were
maintained for at least 60 minutes after a single instillation. These
results must be confirmed in humans due to the physiological
differences between both species that can affect the residence time
of the formulations on the eye surface (i.e. lower blink rate than
humans). In any case, further studies are necessary to demonstrate
the efficacy of these formulations, in terms of ocular surface
damage, that require experimental animal models.
The goal of the study was to enhance the effect of the
hypotensive agent 5-MCA-NAT by using an unpreserved drug
delivery system that could increase its bioavailability while being
soft with the ocular surface. The novel hybrid formulations
simulate tear film composition and include biocompatible
components that might relieve symptoms of secondary diseases
affecting the ocular surface derived from the chronic use of anti-
glaucoma topical medications. With these improvements, patient
adherence to topical glaucoma therapy could be enhanced.
Conclusions
A number of applications of liposomes in ophthalmic drug
delivery have been extensively studied [46,47,48,49,50]. The
improvement in the precorneal retention, transcorneal perme-
ation, and therapeutic efficacy has been explored in detail,
providing information about the interaction between liposomes
and ocular tissues. In this work we prepared novel liposomal
formulations dispersed in aqueous solutions of bioadhesive or
amphiphilic block copolymers for the delivery of the ocular
hypotensive agent 5-MCA-NAT. In vivo efficacy studies in rabbits
showed that the hypotensive effect of the drug was remarkably
increased with the combination of liposomes and bioadhesive
polymers and also tear osmolarity decreased significantly for
60 min. This improvement could be attributed to the influence of
liposomes as drug carriers, the increased residence time of the
formulation on the eye surface derived from the mucoadhesive
properties of the polymers and the ability of these hybrid
formulations to simulate and replenish the tear film. Addition of
the thermosensitive polymer poloxamer to the drug-loaded
liposomes was no more effective than the non-liposomal 5-
MCA-NAT. In this work, the application of liposomes combined
with bioadhesive polymers for the improvement of the precorneal
retention of hypotensive drugs has shown potential for further
investigation. In conclusion, hybrid nanosystems composed by
liposomes combined with bioadhesive polymers might serve as
potential ocular drug carriers that prolong drug retention and
improve biocompatibility of the formulations on the ocular
surface.
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